Application Number		09937331	
Filing Date		2001-09-21	
First Named Inventor	Kunz	e	
Art Unit		1723	
Examiner Name	Toby	Glen Soho	
Attorney Docket Numb	er	72.053	

Evernines				0.0	PATENTS	Remove
Examiner Cite Initial* Patent Number Kind Code ¹ Issu		Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
	1	5612580		1987-03-18	Janonis et al.	
	2	6223871		2006-09-29	Steffen, Michael	
	3	5202612		1993-04-13	Yoshida et al	
	4	6084327		2000-07-04	Steffen, Michael	
	5	5019767		1991-05-28	Shirai et al.	
	6	3410528		1968-11-12	Clark et al.	
	7	2427111		1947-09-09	Tolmie, Edgar S	
If you wish	to a	dd additional U.S. Pa	tent citatio	n information p	lease click the Add button.	Add

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		09937331
Filing Date		2001-09-21
First Named Inventor	Kunz	e
Art Unit		1723
Examiner Name	Toby	Glen Soho
Attorney Docket Numb	er	72.053

									_		
Examiner Initial*	Cite No	Publi	cation Number	Kind Code ¹	Publica Date	ition	Name of Pate of cited Docu	entee or Applican ment			
	1	2003	0012041	A1	2003-0	1-16	Steffen, Micha	el			
If you wisl	h to a	dd add	fitional U.S. Publi	shed Ap	plication	citation	n information p	lease click the A	dd butto	on. Add	
					FOREIG	3N PAT	ENT DOCUM	ENTS		Remove	
Examiner Initial*	Cite No	Fore Num	ign Document ber ³	Country Code ²		Kind Code ⁴	Publication Date	Name of Patent Applicant of cite Document		Pages,Columns,Lines where Relevant Passages or Relevan Figures Appear	ть
	1	0964	116	EP		A1	1999-12-15	Grande, Saverio			Z
	2	3901	893	DE			1989-10-08				
	3	9217	854 5	DE			1993-04-03				
If you wisl	h to a	dd add	itional Foreign P	atent Do	cument	citation	information pl	ease click the Ad	d buttor	Add	
				NON	I-PATE	NT LITE	RATURE DO	CUMENTS		Remove	
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.					T5				
	1										
If you wis	If you wish to add additional non-patent literature document citation information please click the Add button Add										
EXAMINER SIGNATURE											
Examiner	Examiner Signature Date Considered										

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

	Application Number		09937331	
INFORMATION DIGGI COURT	Filing Date		2001-09-21	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	First Named Inventor Kunz		Ne .	
	Art Unit		1723	
	Examiner Name Toby		y Glen Soho	
	Attorney Docket Numb	er	72 053	

See Ginz Codes of USPTO Patient Documents at your, USPTO, COD or MEPE P010.4. Existe office in all issued the document, by the Nov letter code (WIPO) Standard ST3.3. "For Legislance patient Comments, the includion of the year of the ringing or the Engeneer patient Consortion, the patient document by American Standard ST3.0. "For Engeneer patient Consortion, the Post patient document of the Standard ST3.0." Stan

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

	Application Number		09937331
Filing Date			2001-09-21
First Named Inventor Kunz		Kunz	e
	Art Unit		1723
	Examiner Name	Toby	Glen Soho
Attorney Docket Number		er	72.053

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

	That each item of information contained in the information disclosure statement was first cited in any communication
П	from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the
_	information disclosure statement. See 37 CFR 1 97(e)(1)

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, to let not information contained in the information disclosure statement was known to any individual designated in 37 CFR 13/60, more than three months prior to the filing of the information disclosure statement Sex 37 CFR 13/60, to

-	Con attacked and finalise statement	

Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

Timothy F Newholm

7 None

Name/Print

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Registration Number

34400

Signature	/Timothy E. Newholm/	Date (YYYY-MM-DD)	2006-09-29			

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is not lie and by the USPTO to process) an application. Confidentially is governed by \$5 U.S. C. 12.0 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Operatment of Commence, P. 0. Bot 1450, Alexandria, V.3.231-1450, D. NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.3.231-1450.

Privacy Act Statement

The Privacy Act of 1974 (P. L. 95.79) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that. (1) the general authority for the collection of this information is \$5 U.S. C. 2(b)(2); (2) furnishing of the information solicide that.) (1) the general authority for the collection of this information is used by the U.S. Patient and Trademan Koffice is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested in the contraction of the contraction of the patient o

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S. C. 552(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designe, during an inspection of records conducted by GSA a part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S. C. 294 and 2906. Such Adeckouse shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the againston pursuant to 35 U.S. C. 12(b) or issuance of a patient pursuant to 35 U.S. C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record vals filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application pare to public insepections or an issued patient.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.